1. An online multidomain lifestyle intervention to prevent cognitive decline in at-risk older adults: a randomized controlled trial.
- Author
-
Brodaty H, Chau T, Heffernan M, Ginige JA, Andrews G, Millard M, Sachdev PS, Anstey KJ, Lautenschlager NT, McNeil JJ, Jorm L, Kochan NA, Maeder A, Welberry H, San Jose JC, Briggs NE, Popovic G, Mavros Y, Almendrales Rangel C, Noble Y, Radd-Vagenas S, Flood VM, O'Leary F, Lampit A, Walton CC, Barr P, Fiatarone Singh M, and Valenzuela M
- Subjects
- Humans, Aged, Female, Male, Middle Aged, Risk Factors, Australia epidemiology, Single-Blind Method, Exercise, Dementia prevention & control, Depression prevention & control, Cognitive Dysfunction prevention & control, Life Style
- Abstract
Effective, scalable dementia prevention interventions are needed to address modifiable risk factors given global burden of dementia and challenges in developing disease-modifying treatments. A single-blind randomized controlled trial assessed an online multidomain lifestyle intervention to prevent cognitive decline over 3 years. Participants were dementia-free community-dwelling Australians aged 55-77 years with modifiable dementia risk factors. Eligible participants (n = 6,104, 64% female) were randomized 1:1 to a personalized schedule of online coaching in two to four modules (targeting physical activity, nutrition, cognitive activity and depression or anxiety) or a control group that received module-eligible information only. At 3 years, the mean change in a global cognitive composite, the primary outcome, was met. The mean changes in z scores were 0.28 (95% confidence interval (CI): 0.25-0.32) for intervention, 0.10 (95% CI: 0.07-0.13) for control and 0.18 (95% CI: 0.13-0.23, P < 0.001) for the between-group difference. Trial-related adverse events occurred in 19 (0.60%) intervention and 1 (0.03%) control participant. Randomization of this internet-delivered lifestyle intervention tailored to individual dementia risk factors resulted in significantly better cognition in older adults over 3 years. This intervention is scalable with the potential for population-level rollout that may delay cognitive decline in the general community. Australian New Zealand ClinicalTrials.gov registration: ACTRN12618000851268., Competing Interests: Competing interests: H.B. has been an advisory board member or consultant to Biogen, Eisai, Eli Lilly, Medicines Australia, Roche, Skin2Neuron Pty, Cranbrook Care and Montefiore Homes. P.S.S. was a member of expert panels for Biogen and Roche in 2020 and 2021. M.V. has a financial interest in and is cofounder and CEO of Skin2Neuron Pty, unrelated to this work. The other authors declare no competing interests., (© 2025. The Author(s), under exclusive licence to Springer Nature America, Inc.)
- Published
- 2025
- Full Text
- View/download PDF